1. Gilead reported positive phase 3 IDEAL data for seladelpar (Livdelzi) in patients with primary biliary cholangitis who had persistent...

1. The European Commission has authorized expanded venetoclax (Venclyxto) combinations for previously untreated chronic lymphocytic leukemia. 2. The approval reinforces...

1. The FDA has expanded the label for guselkumab (Tremfya) to include evidence that it can inhibit progression of structural...

1. Pfizer has committed $650 million upfront in a collaboration with Innovent Biologics that could ultimately reach $10.5 billion in...

Pfizer and Innovent deepen the China biotech licensing wave Pfizer is making another large oncology bet, this time through a...

Caloric restriction and intermittent fasting show mixed human longevity data Caloric restriction remains one of the most robust interventions for...

Exercise continues to outperform pharmacologic longevity strategies Exercise remains the most consistently validated intervention for improving both lifespan and healthspan,...

Metformin remains a leading candidate for pharmacologic longevity intervention Metformin continues to occupy a unique position in longevity medicine because...

GLP-1 receptor agonists move from weight loss into the longevity conversation GLP-1 receptor agonists are quickly shifting from niche metabolic...

Ambient artificial intelligence scribes reduce clinician documentation time by 16 minutes per encounter A large study published in JAMA in...